Android Apple

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

By Yahoo! Finance   |   3 weeks ago
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Sciences Inc. saw its stock plummet following disappointing results from the Phase 3 ReThink-ALZ study of simufilam for Alzheimer's disease. The trial did not meet key endpoints, leading the company to discontinue a second Phase 3 trial.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.